
Chronic Spontaneous Urticaria

Podcasts
All News
Advertisement

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
2
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
3
Genetic Study Links Higher BMI to Perceived Facial Aging, but Causality Remains Unproven
4
Defining AD Disease Flares vs Drug Effects: A Comparative Analysis of Phase 3 Systemic Therapy Trials
5


























